David J. Wullimann

Huddinge, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

EYRAplex platform for quantification of viral antigen-specific IgG responses.

EYRAplex platform for quantification of viral antigen-specific IgG responses.

Journal: Journal of immunological methods

Published: April 01, 2026

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

Journal: EBioMedicine

Published: November 12, 2025

Human T Cell Responses to Flavivirus Vaccines.

Human T Cell Responses to Flavivirus Vaccines.

Journal: European journal of immunology

Published: April 15, 2025

Antigen-specific T cell responses following single and co-administration of tick-borne encephalitis, Japanese encephalitis, and yellow fever virus vaccines: Results from an open-label, non-randomized clinical trial-cohort.

Antigen-specific T cell responses following single and co-administration of tick-borne encephalitis, Japanese encephalitis, and yellow fever virus vaccines: Results from an open-label, non-randomized clinical trial-cohort.

Journal: PLoS neglected tropical diseases

Published: November 13, 2024

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.

Journal: EBioMedicine

Published: May 01, 2024

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

Journal: Journal of hematology

Published: May 14, 2023

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID.

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID.

Journal: EBioMedicine

Published: April 03, 2023

Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age.

Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 14, 2023

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.

Journal: Haematologica

Published: February 13, 2023

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.

Journal: Blood

Published: April 27, 2022

The Karolinska KI/K COVID-19 Immune Atlas: An open resource for immunological research and educational purposes.

The Karolinska KI/K COVID-19 Immune Atlas: An open resource for immunological research and educational purposes.

Journal: Scandinavian journal of immunology

Published: April 07, 2022

MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine.

MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine.

Journal: Molecular medicine (Cambridge, Mass.)

Published: February 18, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026